Lacosamide Pain UCB Pharma: Withdrawal of the marketing authorisation application
Table of contents
On 25 September 2008, UCB Pharma S.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Lacosamide Pain UCB Pharma, for the treatment of diabetic neuropathic pain in adults.
Lacosamide Pain UCB Pharma
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Lacosamide Pain UCB Pharma (PDF/236.91 KB)Adopted
First published: 20/01/2009
Last updated: 20/01/2009
UCB Pharma withdraws its marketing authorisation application for Lacosamide Pain UCB Pharma (PDF/23.92 KB)
First published: 26/09/2008
Last updated: 26/09/2008
Withdrawal letter : Lacosamide Pain UCB Pharma (PDF/31.82 KB)
First published: 25/09/2008
Last updated: 25/09/2008
Questions and answers on the withdrawal of the marketing application for Lacosamide Pain UCB Pharma (PDF/43.79 KB)
First published: 04/11/2008
Last updated: 04/11/2008
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').